HP
EIGR

Hikari Power’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Hikari Power’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,033
Closed -$482K – 98
2017
Q2 		$482K Buy
2,033
+1,689
+491% +$384K 0.07% 65
2017
Q1 		$118K Buy
+344
New +$118K 0.02% 69

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hikari Power's EIGR Position: Q3 2017 in Review

Hikari Power sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 2,033 shares — an estimated $482K sold.

Hikari Power first reported a position in EIGR in Q1 2017 and held it in 2 quarters. The position peaked at $482K in Q2 2017. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

  • Hikari Power reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Hikari Power sold 2,033 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $482K.
  • Hikari Power first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Hikari Power's Eiger BioPharmaceuticals, Inc. position peaked at $482K in Q2 2017.
  • 33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on Hikari Power's 13F filing for Q3 2017, filed 8 Nov 2017.